May 26, 2011

New short interfering RNA-based therapies for glomerulonephritis

Nature Reviews. Nephrology
Hideki Shimizu, Toshiro Fujita


Current treatments for glomerulonephritis are not satisfactory, and the development of new therapies would be indispensable. Short interfering RNAs (siRNAs) are promising candidates for molecular therapy because of their strong and specific gene-silencing effects. Despite rapid progress in research into the therapeutic uses of siRNAs, however, many hurdles must be overcome before siRNA-based therapies can be brought to the clinic. Most in vivo studies of siRNA-based therapy have been limited to local administration or delivery to specific target organs, including the liver. Therapies based on siRNAs for patients with glomerulonephritis show promise, although tissue-specific protocols using siRNAs have not yet been established for this indication. This Review aims to provide an overview of the current challenges in siRNA-based therapy, primarily with respect to glomerular targeting. In addition, novel delivery approaches for glomerulus-targeted, siRNA-based therapies are described.

  • References103
  • Citations4

Mentioned in this Paper

RNA, Small Interfering
Bright Disease
Renal Glomerular Disease
Kidney Glomerulus
Genetic Therapy, Somatic
Short Hairpin RNA
Therapeutic Uses

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

The Lancet Infectious Diseases
Jonathan R CarapetisMartin Weber
Pediatric Nephrology : Journal of the International Pediatric Nephrology Association
T Matthew EisonRobert J Wyatt
© 2020 Meta ULC. All rights reserved